Mesoblast Limited - ASX: MSB.......USOTC: MBLTY
Mesoblast is a world leader in developing innovative cellular medicines.
We have established what we believe is the industry’s most clinically advanced and diverse portfolio of cell-based products with three programs in active Phase 3 clinical studies.
Our lead product candidates under investigation are:
- MPC-150-IM for chronic heart failure
- MPC-06-ID for chronic low back pain due to disc degeneration
- MSC-100-IV for acute graft versus host disease
- MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy
We also have a strong emerging pipeline of products for follow-on indications.